“A leading healthcare software company in Europe.”
Investment thesis
Our investment thesis is built on several attractive attributes:
- A structural growth market across Europe benefitting from megatrends (healthcare, digitalization, local business w/o global supply chain exposure), accelerated by favourable short-to-mid-term subsidy programs (e.g. KHZG in Germany)
- Nexus has strong market positions in its focus markets (e.g. Switzerland, Germany, Netherlands)
- Scalable software business model with historically high recurring revenues (>50%), high EBITDA margins (>20%) and a strong cash conversion (>60%)
- The company is active in a still fragmented market and has a proven and successful M&A track record financed by internal cash generation
- Particularly strong management which is well-aligned through significant shareholding
Achievements
- Appointment of Florian Herger to the Nexus supervisory board